Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial
<p><strong>Background</strong> Primary spontaneous pneumothorax occurs in otherwise healthy young patients. Optimal management is not defined and often results in prolonged hospitalisation. Data on efficacy of ambulatory options are poor. We aimed to describe the duration of hospit...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1797056661893939200 |
|---|---|
| author | Hallifax, R McKeown, E Sivakumar, P Fairbairn, I Peter, C Leitch, A Knight, M Stanton, A Ijaz, A Marciniak, S Cameron, J Bhatta, A Blyth, K Reddy, R Harris, M-C Maddekar, N Walker, S West, A Laskawiec-Szkonter, M Corcoran, J Gerry, S Roberts, C Harvey, J Maskell, N Miller, R Rahman, N |
| author_facet | Hallifax, R McKeown, E Sivakumar, P Fairbairn, I Peter, C Leitch, A Knight, M Stanton, A Ijaz, A Marciniak, S Cameron, J Bhatta, A Blyth, K Reddy, R Harris, M-C Maddekar, N Walker, S West, A Laskawiec-Szkonter, M Corcoran, J Gerry, S Roberts, C Harvey, J Maskell, N Miller, R Rahman, N |
| author_sort | Hallifax, R |
| collection | OXFORD |
| description | <p><strong>Background</strong>
Primary spontaneous pneumothorax occurs in otherwise healthy young patients. Optimal management is not defined and often results in prolonged hospitalisation. Data on efficacy of ambulatory options are poor. We aimed to describe the duration of hospitalisation and safety of ambulatory management compared with standard care.</p>
<p><strong>Methods</strong>
In this open-label, randomised controlled trial, adults (aged 16–55 years) with symptomatic primary spontaneous pneumothorax were recruited from 24 UK hospitals during a period of 3 years. Patients were randomly assigned (1:1) to treatment with either an ambulatory device or standard guideline-based management (aspiration, standard chest tube insertion, or both). The primary outcome was total length of hospital stay including re-admission up to 30 days after randomisation. Patients with available data were included in the primary analysis and all assigned patients were included in the safety analysis. The trial was prospectively registered with the International Standard Randomised Clinical Trials Number, ISRCTN79151659.</p>
<p><strong>Findings</strong>
Of 776 patients screened between July, 2015, and March, 2019, 236 (30%) were randomly assigned to ambulatory care (n=117) and standard care (n=119). At day 30, the median hospitalisation was significantly shorter in the 114 patients with available data who received ambulatory treatment (0 days [IQR 0–3]) than in the 113 with available data who received standard care (4 days [IQR 0–8]; p<0·0001; median difference 2 days [95% CI 1–3]). 110 (47%) of 236 patients had adverse events, including 64 (55%) of 117 patients in the ambulatory care arm and 46 (39%) of 119 in the standard care arm. All 14 serious adverse events occurred in patients who received ambulatory care, eight (57%) of which were related to the intervention, including an enlarging pneumothorax, asymptomatic pulmonary oedema, and the device malfunctioning, leaking, or dislodging.</p>
<p><strong>Interpretation</strong>
Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events. This data suggests that primary spontaneous pneumothorax can be managed for outpatients, using ambulatory devices in those who require intervention.</p>
<p><strong>Funding</strong>
UK National Institute for Health Research.</p> |
| first_indexed | 2024-03-06T19:25:46Z |
| format | Journal article |
| id | oxford-uuid:1ba52975-b25d-4d9e-8d96-43903c65c584 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:25:46Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:1ba52975-b25d-4d9e-8d96-43903c65c5842022-03-26T11:01:36ZAmbulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1ba52975-b25d-4d9e-8d96-43903c65c584EnglishSymplectic ElementsElsevier2020Hallifax, RMcKeown, ESivakumar, PFairbairn, IPeter, CLeitch, AKnight, MStanton, AIjaz, AMarciniak, SCameron, JBhatta, ABlyth, KReddy, RHarris, M-CMaddekar, NWalker, SWest, ALaskawiec-Szkonter, MCorcoran, JGerry, SRoberts, CHarvey, JMaskell, NMiller, RRahman, N<p><strong>Background</strong> Primary spontaneous pneumothorax occurs in otherwise healthy young patients. Optimal management is not defined and often results in prolonged hospitalisation. Data on efficacy of ambulatory options are poor. We aimed to describe the duration of hospitalisation and safety of ambulatory management compared with standard care.</p> <p><strong>Methods</strong> In this open-label, randomised controlled trial, adults (aged 16–55 years) with symptomatic primary spontaneous pneumothorax were recruited from 24 UK hospitals during a period of 3 years. Patients were randomly assigned (1:1) to treatment with either an ambulatory device or standard guideline-based management (aspiration, standard chest tube insertion, or both). The primary outcome was total length of hospital stay including re-admission up to 30 days after randomisation. Patients with available data were included in the primary analysis and all assigned patients were included in the safety analysis. The trial was prospectively registered with the International Standard Randomised Clinical Trials Number, ISRCTN79151659.</p> <p><strong>Findings</strong> Of 776 patients screened between July, 2015, and March, 2019, 236 (30%) were randomly assigned to ambulatory care (n=117) and standard care (n=119). At day 30, the median hospitalisation was significantly shorter in the 114 patients with available data who received ambulatory treatment (0 days [IQR 0–3]) than in the 113 with available data who received standard care (4 days [IQR 0–8]; p<0·0001; median difference 2 days [95% CI 1–3]). 110 (47%) of 236 patients had adverse events, including 64 (55%) of 117 patients in the ambulatory care arm and 46 (39%) of 119 in the standard care arm. All 14 serious adverse events occurred in patients who received ambulatory care, eight (57%) of which were related to the intervention, including an enlarging pneumothorax, asymptomatic pulmonary oedema, and the device malfunctioning, leaking, or dislodging.</p> <p><strong>Interpretation</strong> Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events. This data suggests that primary spontaneous pneumothorax can be managed for outpatients, using ambulatory devices in those who require intervention.</p> <p><strong>Funding</strong> UK National Institute for Health Research.</p> |
| spellingShingle | Hallifax, R McKeown, E Sivakumar, P Fairbairn, I Peter, C Leitch, A Knight, M Stanton, A Ijaz, A Marciniak, S Cameron, J Bhatta, A Blyth, K Reddy, R Harris, M-C Maddekar, N Walker, S West, A Laskawiec-Szkonter, M Corcoran, J Gerry, S Roberts, C Harvey, J Maskell, N Miller, R Rahman, N Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial |
| title | Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial |
| title_full | Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial |
| title_fullStr | Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial |
| title_full_unstemmed | Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial |
| title_short | Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial |
| title_sort | ambulatory management of primary spontaneous pneumothorax an open label randomised controlled trial |
| work_keys_str_mv | AT hallifaxr ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT mckeowne ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT sivakumarp ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT fairbairni ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT peterc ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT leitcha ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT knightm ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT stantona ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT ijaza ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT marciniaks ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT cameronj ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT bhattaa ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT blythk ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT reddyr ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT harrismc ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT maddekarn ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT walkers ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT westa ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT laskawiecszkonterm ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT corcoranj ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT gerrys ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT robertsc ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT harveyj ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT maskelln ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT millerr ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial AT rahmann ambulatorymanagementofprimaryspontaneouspneumothoraxanopenlabelrandomisedcontrolledtrial |